Introduction {#Sec1}
============

Following the discovery of the lysosome by the Nobel Prize winner Christian de Duve in 1955 (De Duve et al. [@CR6]), research into the biochemistry, molecular biology and pathology of the lysosomal system unravelled many of its functions.

Nowadays, genetic lysosomal storage disorders (LSDs) represent a group of about 50 disorders (Scriver et al. [@CR31]; Staretz-Chacham et al. [@CR34]). All of them are characterized by intralysosomal accumulation of compound(s), e.g., enzyme substrates or products, mishandled bioconjugates, or segregated cytoplasmic components, in a variety of cell types and tissues. Most LSDs result from a deficient enzyme activity caused by a mutation in the gene encoding either the relevant enzyme, protecting protein, protein activators, or the endoplasmic reticulum--Golgi enzyme systems responsible for proper protein posttranslational modification. However, some are caused by dysfunction of the lysosomal system itself due to mutations in genes encoding lysosomal membrane components or components closely associated with the lysosomal system (Saftig [@CR30]; Jalanko and Braulke [@CR15]). The number of lysosomal enzymes and non-catalytic proteins reported in the literature has steadily increased and, therefore, more defects in the lysosomal system are expected to be discovered. The progress in the research into LIMP-2 deficiency serves as a recent example (Balreira et al. [@CR3]; Berkovic et al. [@CR4]).

Overall frequencies of occurrence of LSDs have been reported for several countries (Meikle et al. [@CR20]; Poorthuis et al. [@CR29]; Applegarth et al. [@CR1]; Dionisi-Vici et al. [@CR8]; Pinto et al. [@CR28]), while other reports focused on LSD groups (e.g., mucopolysaccharidoses, (MPS): Nelson et al. [@CR25]; Baehner et al. [@CR2]; Malm et al. [@CR19]; lipidoses: Ozkara and Topcu [@CR26]; neuronal ceroid lipofuscinoses, NCL: Claussen et al. [@CR5]), or on particular LSDs (e.g., MPS I: Moore et al. [@CR23]; metachromatic leukodystrophy and Krabbe disease: Heim et al. [@CR12]). The frequency of LSDs as a group varies among populations from 7.6 to 25 per 100,000 (Meikle et al. [@CR20]; Poorthuis et al. [@CR29]; Applegarth et al. [@CR1]; Dionisi-Vici et al. [@CR8]; Pinto et al. [@CR28]).

The aim of this study was to calculate the birth prevalence and carrier frequencies of LSDs in the Czech Republic population, and to compare our results with reported epidemiologic data from other populations.

Patients and methods {#Sec2}
====================

We analyzed data from individuals who had been diagnosed with a LSD at the Institute of Inherited Metabolic Disorders in Prague between 1975 and 2008. Our Institute is the only laboratory providing diagnostic testing for LSDs, including prenatal testing, in the Czech Republic. The patients had been referred to, or their blood samples had been sent to, the Institute by Departments of Paediatrics, Neurology, Haematology, Cardiology, Nephrology, Dermatology, Gastroenterology, Ophthalmology, Pathology, and Clinical Genetics from hospitals all over the country.

The initial diagnosis of most LSDs was based on demonstration of accumulated substrates (e.g., sphingolipids, oligosaccharides, or glycosaminoglycans) in tissues and/or body fluids using chromatographic or electrophoretic methods, or on histological proof of storage. The definite diagnosis was made by demonstrating the deficiency of the relevant enzyme and/or presence of pathogenic mutation, and/or by detection of undegraded substrate by loading tests in cell cultures. Mucolipidosis II was confirmed by detecting elevated activities of multiple lysosomal enzymes in serum and by molecular analysis. Patients with unspecified types of MPS or NCL, who had died before the availability of confirmatory tests, were also included in the birth prevalence calculation. Their diagnosis was based on biochemical analyses of storage compound, evaluation of clinical data, and histochemical and/or ultrastructural examinations of samples obtained at biopsy or autopsy.

For the calculation of the prevalence, we used the method published by Poorthuis et al. ([@CR29]). The prevalence was calculated as the total number of patients diagnosed with a particular LSD, divided by the total number of live births in the same period, as was the birth period of the diagnosed cases (i.e., the birth period is the interval between the year of the birth of the oldest patient and the year of the birth of the youngest patient). Birth prevalence was expressed as the number of patients per 100,000 live births. The total number of live births in particular years was calculated using birth rates taken from the Czech Statistical Office web page. To avoid underestimation, some patients were not included into the prevalence calculation (e.g., patients born before 1945 were excluded). If there was only one patient diagnosed with the disease, the prevalence was calculated using the number of live births (i.e., 4,261,897) in the examined period (i.e., between 1975 and 2008), as used previously by Pinto et al. ([@CR28]). Familial cases and 11 affected fetuses \[Fabry disease (1), Niemann-Pick disease type C (1), MPS I (3), MPS III A (3) and MPS IV A (3)\] were also included in the calculation of birth prevalence.

For some specific LSDs, the patient group consisted of subgroups with distinct clinical phenotypes (e.g., MLD, Gaucher disease). Using the method mentioned above, we calculated the prevalence of the subgroups separately, and the overall prevalence of the specific LSD was estimated as a sum of the prevalences in the subgroups (Poorthuis et al. [@CR29]).

Calculation of the frequency of Fabry disease was done using two approaches, i.e., excluding and including female heterozygotes. Exclusion of heterozygotes (*n* = 78) enabled us to compare the prevalence to other reported male-specific prevalence data (Meikle et al. [@CR20]; Poorthuis et al. [@CR29]; Ozkara and Topcu [@CR26]; Pinto et al. [@CR28]). Fabry heterozygotes, who can be as severely affected as male patients, are nowadays classified as "patients" instead of "carriers of the defective gene" (Dobrovolny et al. [@CR9]; Wang et al. [@CR37]; Gibas et al. [@CR11]). Therefore, we also calculated the prevalence including Fabry females.

Confidence intervals (95%) for the birth prevalences were estimated from the Poisson distribution using SISA (Simple Interactive Statistical Analysis) software (Uitenbroek [@CR36]). Carrier frequency was calculated using the Hardy--Weinberg equation (Strachan and Read [@CR35]).

Results {#Sec3}
=======

In the past three decades, a total of 478 patients have been diagnosed with one of 34 specific types of LSDs in the Czech Republic (Fig. [1](#Fig1){ref-type="fig"}). The number of diagnosed patients gradually increased during the study period, from less than 10 cases per year in the 1970s to 20--30 new cases diagnosed annually in recent years (Fig. [2](#Fig2){ref-type="fig"}). More than half of all LSD patients had a lipidosis, about one-quarter a mucopolysaccharidosis, and the remaining quarter suffered from NCL, GSD II, mucolipidoses, or glycoproteinoses (Fig. [1](#Fig1){ref-type="fig"}). The combined birth prevalence for all LSDs is 12.25 (95% CI 6.25--24.1) per 100,000 live births. Data on patients with lipidoses, mucopolysaccharidoses, and other LSDs detected during the study period, including carrier frequencies in the Czech population, are summarized in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, respectively. Detailed data on the birth prevalence of specific disorders and their subtypes can be found in Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}. Fig. 1Relative rate of lysosomal storage disorders in the Czech Republic.*MPS* Mucopolysaccharidosis,*NCL* neuronal ceroidlipofuscinosis,*GSD II* glycogenosis type II,*ML* mucolipidosis,*GP* glycoproteinosis,*NPA/B/C* Niemann-Pick A/B/C,*MLD* metachromatic leukodystrophy,*CESD* cholesterol ester storage disease,*MSD* multiple sulphatase deficiency,*GM1* GM1 gangliosidosis,*GM2* GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases),*β-Man* β-mannosidosis,*α-Man* α-mannosidosis,*ISSD* infantile sialic acid storage diseaseFig. 2Number of live births (▲) and number of LSD diagnoses (♦) in the Czech population from 1975 to 2008. In 1985, electrophoretic analysis of glycosaminoglycans (*ELFO GAG*) and thin layer chromatography of oligosaccharides *(TLC OLS*) in urine were introduced. From 1990 onwards, enzyme assays for mucopolysaccharidoses and glycoproteinoses were gradually introduced. Nowadays, laboratory diagnostic methods for 45 LSDs are available (enzyme and DNA analyses, loading assays)Table 1Lipidoses: comparison of data in different populationsDiseaseCzech RepublicOther countriesNo. of patients 1975--2008^a^Prevalence per 100,000^b^Poisson 95% confidence intervalCarrier frequency^c^ × 10^3^NLPortugalAustraliaTurkeyPrevalence per 100,000 live birthsGaucher (all types)491.130.61--1.956.711.161.351.750.45Niemann-Pick A/B230.330.16--0.613.650.530.60.4Niemann-Pick C540.910.67--1.216.020.352.20.47Fabry male490.52 (1.0)^d^0.38--0.690.010.210.120.860.015Fabry female780.770.60--0.98Krabbe150.400.21--0.684.01.351.210.711MLD (all types)250.690.29--1.385.261.421.851.091.43CESD, Wolman180.270.15--0.453.310.19GM1 gangliosidosis130.260.14--0.463.250.410.620.260.54GM2 Tay-Sachs100.300.14--0.553.450.413.130.50.23GM2 Sandhoff30.190.04--0.552.740.341.490.260.95Lipidoses all types259^e^/337^f^5.0^e^/5.77^f^2.79 (3.39)--8.53 (9.51)6.212.66.64.6*NL* Netherlands, *MLD* metachromatic leukodystrophy, *CESD* cholesteryl ester storage disease^a^Total number of patients diagnosed between 1975 and 2008^b^Data for prevalence calculations are in Table [4](#Tab4){ref-type="table"}^c^Carrier per 1 live birth^d^Male live births only^e^Fabry females not included^f^Fabry females includedTable 2Mucopolysaccharidoses: comparison of data in different populationsDiseaseCzech RepublicOther countriesNo. of patients 1975--2008^a^Prevalence per 100,000^b^Poisson 95% confidence intervalCarrier frequency^c^ × 10^3^NLPortugalAustraliaGermanyPrevalence per 100,000 live birthsMPS I200.720.44--1.115.381.191.331.140.69MPS II220.43 (0.83)^d^0.26--0.650.00850.671.090.740.64MPS III A180.470.27--0.754.311.1600.88MPS III B10.020.0--0.130.970.420.720.47MPS III C50.420.14--0.994.120.210.120.07MPS III D000.10.10MPS III (all types)240.910.41--1.871.890.841.421.57MPS IV A140.710.38--1.225.350.220.60.59MPS IV B10.020.0--0.130.970.1400MPS IV (A + B)150.730.38--1.350.38MPS VI20.050.01--0.181.400.150.420.430.23MPS VII10.020.0--0.130.970.2400.05MPS unspecified^e^320.600.39--0.87MSD30.260.05--0.773.240.050.480.07MPS all types1193.721.94--6.934.54.84.443.53*NL* Netherlands, *MPS* mucopolysaccharidosis, *MSD* multiple sulphatase deficiency^a^Total number of patients diagnosed between 1975 and 2008^b^Data for prevalence calculations are in Table [5](#Tab5){ref-type="table"}^c^Carrier per 1 live birth^d^Male live births only^e^Unspecified cases of MPS were diagnosed on the basis of analysis of glycosaminoglycan excreted in urine combined with the evaluation of clinical data. No material was available for enzyme and DNA analysisTable 3Glycoproteinoses, mucolipidoses, glycogenosis type II and neuronal ceroid lipofuscinoses: comparison of data in different populationsDiseaseCzech RepublicOther countriesNo. of patients 1975--2008^a^Prevalence per 100,000^b^Poisson 95% confidence intervalCarrier frequency^c^ × 10^3^NLPortugalAustraliaPrevalence per 100,000 live birthsα-Mannosidosis40.380.10--0.983.920.090.120.1β-Mannosidosis20.160.02--0.592.560.130.120ISSD10.020.0--0.130.970.0700.19Fucosidosis00.0500Aspartylglucosaminuria00.131.720.05α-N-acetyl-galactosaminidase def.00.200Galactosialidosis00.040.770Mucolipidosis I30.070.01--0.201.660.0500.02Mucolipidosis II/III30.220.05--0.652.980.240.810.31Mucolipidosis IV10.020.0--0.130.97Glycogenosis type II (all)120.370.13--0.813.8620.170.69NCL 120.190.02--0.702.790.17NCL 2280.360.24--0.523.790.07NCL 320.270.03--0.963.270.48NCL 410.020.0--0.130.97NCL 520.210.03--0.772.92NCL 610.020.0--0.130.971.43NCL 7180.850.49--1.365.81NCL unspecified^d^200.370.22--0.58NCL (all types)742.291.03--5.152.14*NL* Netherlands, *ISSD* infantile sialic acid storage disease, *NCL* neuronal ceroid lipofuscinosis^a^Total number of patients diagnosed between 1975 and 2008^b^Data for prevalence calculations are in Table [6](#Tab6){ref-type="table"}^c^Carrier per 1 live birth^d^Unspecified NCL were diagnosed on the basis of histochemical and ultrastructural examination of biopsy samples combined with the evaluation of clinical data. No material was available for enzyme and DNA analysisTable 4Lipidoses: data for calculation of birth prevalenceDiseaseNo. of patients 1975--2008^a,b^Years of birthNo. of live birthsNo. of patients^c^Prevalence (1 per numbers of live births)Prevalence per 100,000Carrier frequency^d^Gaucher type I, early12 (10)1974--19963 090 90212257 5750.39254Gaucher type I, late29 (28)1945--19805 956 02824248 1680.40249Gaucher type II and III^e^8 (8)1980--19982 352 4928294 0620.34271Gaucher (all types)494488 3971.13149Niemann-Pick A10 (8)1963--20025 480 88510548 0890.18370Niemann-Pick B + atyp^f^13 (11)1948--19967 362 14611669 2860.15409Niemann-Pick A/B2321301 3270.33274Niemann-Pick C^g^54 (45)1965--20035 271 31048109 8190.91166Fabry^h^49 (24)1945--20028 518 60144193 6050.5296 803Male4 382 0684499 5921.00^n^Fabry female78 (24)1945--20058 812 16168129 5910.77Krabbe^i^15 (15)1977--20023 249 15013249 9350.40250MLD infantile13 (11)1970--19994 195 56413322 7360.31284 Juvenile5 (4)1970--20044 661 3245932 2650.11483 Adult7 (7)1968--19802 188 0046364 6670.27302MLD (all types)2524144 6470.69190CESD, Wolman^j^18 (15)1963--20025 480 88515365 3920.27302GM1 gangliosidosis13 (13)1970--20034 563 66012380 3050.26308GM2 Tay-Sachs^k^10 (10)1971--19923 362 88910336 2890.30290GM2 Sandhoff3 (3)1992--20071 594 9493531 6500.19365Lipidoses all types259^l^/337^m^234^l^/302^m^20 0005.0^l^/5.77^m^71^o^*MLD* Metachromatic leukodystrophy, *CESD* cholesteryl ester storage disease^a^Total number of patients diagnosed between 1975 and 2008^b^Number of families with particular disorder in parentheses^c^Number of patients taken for the calculation of birth prevalence. To avoid underestimation, some patients were not included into the prevalence calculation (e.g., patients born before 1945 were excluded). For prevalence definition, see "[Patients and Methods](#Sec2){ref-type="sec"}"^d^Expressed as 1 carrier per number of shown live births^e^One stillborn case^f^NP type B in 6 slowly progressive visceral cases and atypical protracted neurovisceral phenotype in 7 cases \[Pavlů-Pereira H, et al. *J Inherit Metab Dis* 2005;**28**:203--227\]^g^Including one case of NP type C2 \[Elleder M. et al. *Virchows Arch* 2001;**439**:206--211\]^h^Classical phenotype in 43 male patients and cardiac variant in 6 male patients (two families) \[Elleder M, et al. *Cas Lek Cesk* 1990;**129**:368--372\]^i^Infantile form in 12 patients, late infantile in 2 patients, and adult form in one patient \[Kostalova E, et al. *Ceska Slov Neurol Neurochir* 2006;**69/102**:200--210\]^j^One infantile patient (Wolman disease) and 17 juvenile and adult cases \[Elleder M, et al. *Cas Lek Cesk* 1999;**138**:719--724\]^k^Including two adult patients^l^Fabry females not included^m^Fabry females included^n^Male live births^o^Carrier frequency of lipidoses except for Fabry diseaseTable 5Mucopolysaccharidoses: data for calculation of birth prevalenceDiseaseNo. of patients 1975--2008^a,b^Years of birthNo. of live birthsNo. of patients^c^Prevalence (1 per number of live births)Prevalence per 100,000Carrier frequency^d^MPS I20^e^ (17)1984--20082,772,55920138,6280.72186MPS II22 (19)1969--20054,906,70021233,6520.43116,826Male2,520,37321120,0180.83^f^MPS III A18 (14)1977--20063,648,54117214,6200.47232MPS III B11975--20084,261,89714,261,8970.021,032MPS III C5 (4)1984--19921,179,7455235,9490.42243MPS III (all types)2423109,5020.91165MPS IV A14 (9)1987--20031,826,47313140,4980.71187MPS IV B11975--20084,261,89714,261,8970.021,032MPS IV (A + B)1514136,9860.73185MPS VI2 (2)1968--19954,115,05722,057,5290.05717MPS VII11975--20084,261,89714,261,8970.021,032MPS I--VII848134,9092.8693MPS-unspecified32 (27)1960--19894,533,49627167,9070.60205MSD3 (1)1962--19691,144,4673381,4890.26309MPS all types11911126,8653.7282^g^*MPS* mucopolysaccharidosis, *MSD* multiple sulphatase deficiency^a^Total number of patients diagnosed between 1975 and 2008^b^Number of families with particular disorder in parentheses^c^Number of patients taken for the calculation of birth prevalence. To avoid underestimation, some patients were not included into the prevalence calculation (e.g., patients born before 1945 were excluded). For prevalence definition, see "[Patients and Methods](#Sec2){ref-type="sec"}"^d^Expressed as 1 carrier per number of shown live births^e^Hurler syndrom in 16 patients, Hurler/Scheie in 2 patients and Scheie syndrom in 2 patients^f^Male live births^g^Carrier frequency of MPS excluding MPS IITable 6Glycoproteinoses, mucolipidoses, glycogenosis type II and neuronal ceroidlipofuscinoses: data for calculation of birth prevalenceDiseaseNo. of patients 1975--2008^a,b^Years of birthNo. of live birthsNo. of patients^c^Prevalence (1 per numbers of live births)Prevalence per 100,000Carrier frequency^d^α-Mannosidosis4 (3)1985--19921,042,8044260,7010.38255β-Mannosidosis2 (1)1950--19561,223,3862611,6930.16391ISSD11975--20084,261,89714,261,8970.021,032Mucolipidosis I3^e^ (2)1969--19994,338,72931,446,2430.07601Mucolipidosis II/III3 (3)1994--20071,352,2193450,7400.22336Mucolipidosis IV1^f^1975--20084,261,89714,261,8970.021,032GP + ML (all types)1414112,9950.87170Glycogenosis type II infantile6 (5)1979--19992,614,0756435,6790.23330Glycogenosis type II juvenile6 (5)1972--20024,167,9306694,6550.14417Glycogenosis type II (all)1212267,7500.37259NCL 12 (2)1970--19751,033,4472516,7240.19359NCL 228 (25)1949--20037,803,06828278,6810.36264NCL 32 (2)1979--1983749,5202374,7600.27306NCL 411975--20084,261,89714,261,8970.021,032NCL 52 (1)1983--1989935,5532467,7770.21342NCL 611975--20084,261,89714,261,8970.021,032NCL 718 (16)1985--20022,002,02517117,7660.85172NCL-unspecified20 (17)1965--19994,903,21418272,4010.37261NCL (all types)747143,5512.29104*ISSD* infantile sialic acid storage disease, *GP* glycoproteinosis, *ML* mucolipidosis, *NCL* neuronal ceroid lipofuscinosis^a^Total number of patients diagnosed between 1975 and 2008^b^Number of families with particular disorder in parentheses^c^Number of patients taken for the calculation of birth prevalence. To avoid underestimation, some patients were not included into the prevalence calculation (e.g. patients born before 1945 were excluded). For prevalence definition see "[Patients and Methods](#Sec2){ref-type="sec"}"^d^Expressed as 1 carrier per number of shown live births^e^One infantile patient and two juvenile siblings with cherry-red spot myoclonus syndrome \[Ledvinova J, et al. *J Inherit Metab Dis* 1994;**17**:118--119\]^f^Atypical case of ML IV with ocular restricted phenotype \[Dobrovolny R, et al. *Am J Ophthalmol* 2007; **143**:663--671\]

To date, no individuals in the Czech population have been conclusively diagnosed with Farber disease, Schindler disease, Danon disease, Sanfilippo D disease, galactosialidosis, fucosidosis, aspartylglucosaminuria, or prosaposin, saposins, or GM2 activator protein deficiencies.

Discussion {#Sec4}
==========

The overall prevalence of LSDs in the Czech population (12.25 per 100,000), which represents a typical Central European population, is comparable to prevalences reported for Australia (12.9 per 100,000), the Netherlands (14 per 100,000) and Italy (12.1 per 100,000) (Meikle et al. [@CR20]; Poorthuis et al. [@CR29]; Dionisi-Vici et al. [@CR8]). The higher prevalence of LSDs reported for the northern Portuguese population (25 per 100,000) might reflect the relative geographic isolation and more extensive studying of that particular population of this region (Pinto et al. [@CR28]). The most frequent single LSD is Gaucher disease in the Czech Republic, Italy and Australia, GM2 gangliosidosis in Portugal, and Pompe disease in the Netherlands.

In the Czech population, lipidoses were most frequently diagnosed (5.0 per 100,000 live births), followed by MPS (3.72) and NCL (2.29). In addition to the LSD diagnoses in Czech patients, 96 cases from Slovakia were confirmed at our Institute during the studied period; 41% with lipidoses, 39% with MPS, and 20% with GSD II or NCLs. These Slovakian patients have not been included in our prevalence calculations as former Czechoslovakia was divided into two independent states, the Czech Republic and the Slovak Republic, in 1993. Interestingly, the four cases of prosaposin deficiency so far diagnosed at our Institute came from neighboring populations (Slovak, German) (Hulkova et al. [@CR13]; Elleder et al. [@CR10]; Kuchar et al. [@CR18]).

The birth prevalence of the most frequent LSD in the Czech Republic, Gaucher disease, is 1.13 per 100,000 live births, followed by Niemann-Pick C (0.91), MPS III (0.91), MPS IV (0.73), and MPS I (0.72). Comparison of these prevalences to those in selected foreign populations (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}) is complicated by the differences in methods used for calculation. When we compared the calculations of prevalence in the Czech population based on the method of Poorthuis et al. ([@CR29]) used in this study (see "[Patients and Methods](#Sec2){ref-type="sec"}") to the method reported by Meikle et al. [@CR20]) (the prevalence calculated as the number of patients divided by the total number of live births during the study period), the calculations resulted in underestimation or overestimations of some individual disorders. This is the case for disorders with delayed onset (e.g., frequencies of Fabry disease were 0.52 and 1.14 per 100,000, and frequencies of cholesterol ester storage disease were 0.27 and 0.42, if calculated using the methods of Poorthuis et al. ([@CR29]) and Meikle et al. ([@CR20]), respectively). Also, unavailability of some diagnostic methods during the study period (some methods were introduced as late as the 1990s) may explain some discrepancies found in our calculations using the two methods. Although prevalence values for some disorders calculated using either of the methods were within the confidence intervals (data not shown), for other disorders prevalence values fell outside this interval (e.g., the frequencies differed for MPS III C (0.42 and 0.11 per 100,000), MPS IVA (0.71 and 0.32), NCL 2 (0.36 and 0.65) and NCL 7 (0.85 and 0.42), if calculated according to the methods used by Poorthuis et al. ([@CR29]) and Meikle et al. ([@CR20]), respectively).

Thus, establishment of standard rules for calculation of birth prevalence-a defined term in clinical epidemiology-is highly recommended. This would enable more reliable comparison of data from different populations. Based on our experience, the calculation of the ratio of the number of patients to the number of live births during the patients' births period (Poorthuis et al. [@CR29]) fits well to the definition of prevalence. Underestimation of the birth prevalence may result from lack of recognition of early clinical signs and symptoms or phenotypic diversity, including adult forms of the disease (e.g., Fabry disease, adult Krabbe disease, adult MLD, cholesteryl ester storage disease, and adult GSD II). Thus, the calculated birth prevalence is probably the lowest estimate as the diagnosis is commonly delayed for years. Screening studies have shown that certain groups of patients, for example individuals with renal failure on haemodialysis, may harbor missed Fabry patients (Nakao et al. [@CR24]; Kotanko et al. [@CR16]). The nationwide screening study among 3,370 chronic haemodialysis patients in the Czech Republic disclosed four previously unrecognized Fabry males and one female from five unrelated families. Subsequent family screening ascertained Fabry disease in another 12 individuals, including 8 females (Merta et al. [@CR21]). Patients with unexplained cardiomyopathy represent another group at risk of having Fabry disease where screening is justified (Monserrat et al. [@CR22]). Such LSD screening initiatives for selected LSDs will contribute to the identification of the true prevalence of these disorders (Spada et al. [@CR33]; Chien et al. [@CR14]).

Fabry heterozygotes have not been included in the calculation of birth prevalence in previous reports (Meikle et al. [@CR20]; Poorthuis et al. [@CR29]; Pinto et al. [@CR28]). However, they commonly develop clinical symptoms and severe complications, generally a few years later, as in affected men (Deegan et al. [@CR7]; Wilcox et al. [@CR38]). When we included Fabry heterozygotes in the calculations, the prevalence of Fabry disease increased by 2.5 times to 1.29 per 100,000 live births, that of lipidoses from 5.0 to 5.77 per 100,000 and the overall prevalence of LSDs reached 13.02 per 100,000 (Table [4](#Tab4){ref-type="table"}). Therefore, we propose that Fabry heterozygotes ought to be included in the calculation of the birth prevalence of Fabry disease.

Reliable calculation of the birth prevalence is dependant on a correctly defined pathogenic cause underlying the condition. Recent molecular studies have provided evidence for at least ten separate genetic loci (CLN1--CLN10) for NCL (Peltonen et al. [@CR27]; Siintola et al. [@CR32]). These new findings necessitated reclassification of our 37 cases that had formerly been provisionally classified as NCL6 into NCL5, NCL6, and NCL7 subgroups. The latter turned out to be of high prevalence in the Roma Gypsy population (Kousi et al. [@CR17]). About a quarter of the NCL cases remain unspecified due to the lack of material suitable for mutation analysis.

Athough specific LSDs are generally reckoned to be rare disorders, as a group of inherited metabolic disorders they are quite common, as seen from published and our data. The information on birth prevalencies of LSDs is available from countries with a long tradition of diagnosis of LSDs; however, for most populations, these date are missing. Epidemiological data on these disorders are important in genetic counselling for calculation of the risk for the disorders in the other members of affected families and subsequently for the public health care systems.

Importantly, awareness of the clinical aspects of these life-threatening and progressively disabling genetic diseases among the medical community should increase, allowing earlier diagnosis. In turn, this will offer an opportunity for early therapeutic intervention. Dependant on the diagnosed disorder, such intervention may include enzyme replacement therapy, bone marrow transplantation, or other current or future therapies. Last but not least, it should be borne in mind that genetic counselling and prenatal diagnosis in families affected by a genetic metabolic disorder still form the basic strategy for lowering the number of patients with these severe disorders.
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